{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:44:56Z","timestamp":1786999496838,"version":"build-2736575974"},"reference-count":23,"publisher":"Cambridge University Press (CUP)","issue":"8","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Infect. Control Hosp. Epidemiol."],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S0899823X20001762_as1\" sec-type=\"other\">\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      The data regarding the effectiveness of chemical prophylaxis against recurrent\n                      <jats:italic>C. difficile<\/jats:italic>\n                      infection (CDI) remain conflicting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X20001762_as2\" sec-type=\"other\">\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective cohort study on the effectiveness of oral vancomycin for prevention of recurrent CDI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X20001762_as3\" sec-type=\"other\">\n                    <jats:title>Setting:<\/jats:title>\n                    <jats:p>Two academic centers in New York.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X20001762_as4\" sec-type=\"other\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Two participating hospitals implemented an automated alert recommending oral vancomycin 125 mg twice daily in patients with CDI history scheduled to receive systemic antimicrobials. Measured outcomes included breakthrough and recurrent CDI rates, defined as CDI during and 1 month after initiation of prophylaxis, respectively. A self-controlled, before-and-after study design was employed to examine the effect of vancomycin prophylaxis on the prevalence of vancomycin-resistant\n                      <jats:italic>Enterococcus<\/jats:italic>\n                      spp (VRE) colonization and infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X20001762_as5\" sec-type=\"other\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We included 264 patients in the analysis. Breakthrough CDI was identified in 17 patients (6.4%; 95% confidence interval [CI], 3.8%\u201310.1%) and recurrent in 22 patients (8.3%; 95% CI, 5.3%\u201312.3%). Among the 102 patients with a history of CDI within the 3 months preceding prophylaxis, 4 patients (3.9%; 95% CIs, 1.1%\u20139.7%) had breakthrough CDI and 9 had recurrent disease (8.8%; 95% CIs, 4.1%\u201316.1%). In the 3-month period following vancomycin prophylaxis, we detected a statistically significant increase in both the absolute number of VRE (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      , 0.003) and the ratio of VRE to VSE isolates (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      , 0.003) compared to the combined period of 1.5 months preceding and the 3\u20134.5 months following prophylaxis. This effect persisted 6 months following prophylaxis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0899823X20001762_as6\" sec-type=\"other\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Prophylactic vancomycin is an effective strategy to prevent CDI recurrence, but it increases the risk of VRE colonization. Thus, a careful selection of patients with high benefit-to-risk ratio is needed for the implementation of this preventive policy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/ice.2020.176","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:48:50Z","timestamp":1592268530000},"page":"908-913","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":8,"title":["Oral vancomycin prophylaxis against recurrent\n                    <i>Clostridioides difficile<\/i>\n                    infection: Efficacy and side effects in two hospitals"],"prefix":"10.1017","volume":"41","author":[{"given":"Ioannis M.","family":"Zacharioudakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fainareti N.","family":"Zervou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina","family":"Dubrovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"S0899823X20001762_ref21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-177"},{"key":"S0899823X20001762_ref23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00090-08"},{"key":"S0899823X20001762_ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306801"},{"key":"S0899823X20001762_ref14","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/j.1572-0241.1998.00541.x","article-title":"Clostridium difficile colitis: factors influencing treatment failure and relapse\u2014a prospective evaluation","volume":"93","author":"Nair","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"S0899823X20001762_ref12","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.59"},{"key":"S0899823X20001762_ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-017-0210-3"},{"key":"S0899823X20001762_ref3","unstructured":"3. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf. Published 2013. Accessed January 5, 2018."},{"key":"S0899823X20001762_ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw217"},{"key":"S0899823X20001762_ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205037"},{"key":"S0899823X20001762_ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801550"},{"key":"S0899823X20001762_ref8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis356"},{"key":"S0899823X20001762_ref9","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2014.88"},{"key":"S0899823X20001762_ref10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis462"},{"key":"S0899823X20001762_ref11","first-page":"CD006095","article-title":"Probiotics for the prevention of Clostridium difficile\u2013associated diarrhea in adults and children","volume":"12","author":"Goldenberg","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"S0899823X20001762_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.02.040"},{"key":"S0899823X20001762_ref16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy149"},{"key":"S0899823X20001762_ref17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw401"},{"key":"S0899823X20001762_ref18","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.417"},{"key":"S0899823X20001762_ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017727756"},{"key":"S0899823X20001762_ref20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy822"},{"key":"S0899823X20001762_ref22","first-page":"217","article-title":"Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management","volume":"8","author":"O\u2019Driscoll","year":"2015","journal-title":"Infect Drug Resist"},{"key":"S0899823X20001762_ref13","unstructured":"13. Prepublication requirements: new antimicrobial stewardship standard. The Joint Commision website. https:\/\/www.jointcommission.org\/assets\/1\/6\/HAP-CAH_Antimicrobial_Prepub.pdf. Published June 22, 2016. Accessed December 16, 2018."},{"key":"S0899823X20001762_ref2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu125"}],"container-title":["Infection Control &amp; Hospital Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0899823X20001762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T09:06:26Z","timestamp":1616231186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0899823X20001762\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0899823X20001762"],"URL":"https:\/\/doi.org\/10.1017\/ice.2020.176","relation":{},"ISSN":["0899-823X","1559-6834"],"issn-type":[{"value":"0899-823X","type":"print"},{"value":"1559-6834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"\u00a9 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}